Nuo Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 14, 2023 and accepted by EDGAR at Aug 14, 2023, 20:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $118.2k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $179.3k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $20.5k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $30.9k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | $97.7k | us-gaap:GrossProfit |
| Gross profit | 6 months2023-01-01 to 2023-06-30 | $148.4k | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $969.1k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-06-30 | $1.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$871.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$871.9k | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$1.7m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$1.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $5.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $344.4k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $1.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $1.4m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $703.4k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $914.4k | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-06-30 | $470.8k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-23-023710. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.